戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 mmation in the lung of patients with chronic beryllium disease.
2 ould serve as a possible therapy for chronic beryllium disease.
3 ify both beryllium sensitization and chronic beryllium disease.
4  at position 69 (HLA-DPB1(Glu69)) in chronic beryllium disease.
5  response to beryllium and in progression to beryllium disease.
6 orted to be strongly associated with chronic beryllium disease.
7                    Susceptibility to chronic beryllium disease, a granulomatous lung disease that app
8 osure in the workplace can result in chronic beryllium disease, a granulomatous lung disorder charact
9  for sarcoidosis and, in contrast to chronic beryllium disease, a non-E(69)-containing allele, HLA-DP
10 1) idiopathic pulmonary fibrosis, 2) chronic beryllium disease and sarcoidosis, 3) control subjects w
11 cent insights into Ag recognition in chronic beryllium disease and sarcoidosis.
12 time between those who progressed to chronic beryllium disease and those who remained sensitized with
13 mong BAL cells of patients with sarcoidosis, beryllium disease, and hypersensitivity pneumonitis.
14                      Sarcoidosis and chronic beryllium disease are noninfectious lung diseases that a
15 biopsies to determine progression to chronic beryllium disease as evidenced by granulomatous inflamma
16 LA DPB1 locus, a SNP associated with chronic beryllium disease, as well as HLA DPA1 alleles using the
17 ls with beryllium sensitization have chronic beryllium disease at the time of their initial clinical
18 me (ACE) genotype is associated with chronic beryllium disease (CBD) and disease severity, we studied
19 B1 gene (Glu(69)) is associated with chronic beryllium disease (CBD) and possibly beryllium sensitiza
20 ic and clinical similarities between chronic beryllium disease (CBD) and sarcoidosis suggest that sim
21 suggests a genetic predisposition to chronic beryllium disease (CBD) and sarcoidosis, which are clini
22                                      Chronic beryllium disease (CBD) is a fibrotic lung disorder caus
23                                      Chronic beryllium disease (CBD) is a granulomatous disorder char
24                                      Chronic beryllium disease (CBD) is a granulomatous lung disease
25                                      Chronic beryllium disease (CBD) is a granulomatous lung disorder
26                                      Chronic beryllium disease (CBD) is a hypersensitivity disorder c
27                                      Chronic beryllium disease (CBD) is a hypersensitivity granulomat
28                                      Chronic beryllium disease (CBD) is an occupational lung disorder
29                                      Chronic beryllium disease (CBD) is associated with the allelic s
30                                      Chronic beryllium disease (CBD) is caused by beryllium exposure
31                                      Chronic beryllium disease (CBD) is caused by exposure to berylli
32                                      Chronic beryllium disease (CBD) is caused by workplace exposure
33                                      Chronic beryllium disease (CBD) is characterized by a CD4+ T cel
34                                      Chronic beryllium disease (CBD) is characterized by granulomatou
35                    Susceptibility to chronic beryllium disease (CBD) is linked to certain HLA-DP mole
36                                      Chronic beryllium disease (CBD) provides a human disorder in whi
37                                      Chronic beryllium disease (CBD) provides a model for study of th
38                                      Chronic beryllium disease (CBD) provides a model system in which
39 rom HLA-DP2-expressing patients with chronic beryllium disease (CBD), a debilitating granulomatous lu
40 CII allele, HLA-DP2, are at risk for chronic beryllium disease (CBD), a debilitating inflammatory lun
41 ecific granulomatous inflammation of chronic beryllium disease (CBD), and compared it with that in he
42 ies demonstrate associations between chronic beryllium disease (CBD), beryllium sensitization (BeS),
43  beryllium-specific CD4+ T cells and chronic beryllium disease (CBD), which is characterized by the p
44  can lead to sensitization (BeS) and chronic beryllium disease (CBD).
45 ronchoalveolar lavage (BAL) cells in chronic beryllium disease (CBD).
46 iologic measures in 57 patients with chronic beryllium disease (CBD).
47 n and nonspecific effects leading to chronic beryllium disease (CBD).
48           We studied this process in chronic beryllium disease, in which the frequency of antigen-spe
49                                      Chronic beryllium disease is a lung disorder caused by beryllium
50                                      Chronic beryllium disease is caused by occupational exposure to
51 sion from beryllium sensitization to chronic beryllium disease is unknown.
52 in idiopathic pulmonary fibrosis and chronic beryllium disease lung tissues and interacted with hepar
53 ific TCRs derived from the lung of a chronic beryllium disease patient.
54 ryllium-specific CD4(+) T cells from chronic beryllium disease patients remain CD28-dependent, while
55 lar lavage (BAL) CD4(+) T cells from chronic beryllium disease patients to identify possible therapeu
56  blood and bronchoalveolar lavage of chronic beryllium disease patients up-regulate 4-1BB expression,
57 cell lines derived from the lungs of chronic beryllium disease patients, beryllium presentation to th
58 (+) T cells recruited to the lung in chronic beryllium disease recognize beryllium in an Ag-specific
59                                      Chronic beryllium disease results from beryllium exposure in the